Neogenomics annual operating margin
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Neogenomics's operating margin was −15.93% for fiscal 2025.
View full Neogenomics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −15.93% | −1.99 pp |
| 2024 | 2024-12-31 | −13.94% | +4.27 pp |
| 2023 | 2023-12-31 | −18.21% | +12.71 pp |
| 2022 | 2022-12-31 | −30.92% | −6.40 pp |
| 2021 | 2021-12-31 | −24.52% | −21.37 pp |
| 2020 | 2020-12-31 | −3.15% | −6.33 pp |
| 2019 | 2019-12-31 | 3.18% | −0.45 pp |
| 2018 | 2018-12-31 | 3.63% | +2.42 pp |
| 2017 | 2017-12-31 | 1.21% | +0.28 pp |
| 2016 | 2016-12-31 | 0.93% | +6.31 pp |
| 2015 | 2015-12-31 | −5.38% | −7.79 pp |
| 2014 | 2014-12-31 | 2.41% | −2.03 pp |
| 2013 | 2013-12-31 | 4.44% | +2.57 pp |
| 2012 | 2012-12-31 | 1.87% | +2.81 pp |
| 2011 | 2011-12-31 | −0.94% | +7.68 pp |
| 2010 | 2010-12-31 | −8.62% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −4.85% | +21.42 pp |
| Q1 2026 | 2026-03-31 | −9.77% | +6.79 pp |
| Q4 2025 | 2025-12-31 | −7.05% | +3.64 pp |
| Q3 2025 | 2025-09-30 | −14.38% | −1.75 pp |
| Q2 2025 | 2025-06-30 | −26.27% | −12.93 pp |
| Q1 2025 | 2025-03-31 | −16.56% | +3.01 pp |
| Q4 2024 | 2024-12-31 | −10.70% | +1.24 pp |
| Q3 2024 | 2024-09-30 | −12.63% | +3.29 pp |
| Q2 2024 | 2024-06-30 | −13.34% | +7.01 pp |
| Q1 2024 | 2024-03-31 | −19.56% | +6.00 pp |
| Q4 2023 | 2023-12-31 | −11.94% | +7.08 pp |
| Q3 2023 | 2023-09-30 | −15.92% | +14.76 pp |
| Q2 2023 | 2023-06-30 | −20.35% | +11.40 pp |
| Q1 2023 | 2023-03-31 | −25.56% | +18.84 pp |
| Q4 2022 | 2022-12-31 | −19.02% | +14.04 pp |
| Q3 2022 | 2022-09-30 | −30.68% | +2.05 pp |
| Q2 2022 | 2022-06-30 | −31.74% | −13.37 pp |
| Q1 2022 | 2022-03-31 | −44.40% | −31.33 pp |
| Q4 2021 | 2021-12-31 | −33.06% | −37.46 pp |
| Q3 2021 | 2021-09-30 | −32.73% | −36.45 pp |
| Q2 2021 | 2021-06-30 | −18.38% | +3.36 pp |
| Q1 2021 | 2021-03-31 | −13.08% | −8.08 pp |
| Q4 2020 | 2020-12-31 | 4.40% | +2.22 pp |
| Q3 2020 | 2020-09-30 | 3.72% | +0.23 pp |
| Q2 2020 | 2020-06-30 | −21.74% | −26.14 pp |
| Q1 2020 | 2020-03-31 | −4.99% | −7.66 pp |
| Q4 2019 | 2019-12-31 | 2.17% | −1.52 pp |
| Q3 2019 | 2019-09-30 | 3.50% | −2.18 pp |
| Q2 2019 | 2019-06-30 | 4.40% | +3.23 pp |
| Q1 2019 | 2019-03-31 | 2.67% | −1.28 pp |
| Q4 2018 | 2018-12-31 | 3.69% | −2.34 pp |
| Q3 2018 | 2018-09-30 | 5.67% | +9.16 pp |
| Q2 2018 | 2018-06-30 | 1.17% | −1.78 pp |
| Q1 2018 | 2018-03-31 | 3.95% | +4.96 pp |
| Q4 2017 | 2017-12-31 | 6.03% | +11.58 pp |
| Q3 2017 | 2017-09-30 | −3.49% | −5.79 pp |
| Q2 2017 | 2017-06-30 | 2.96% | −0.52 pp |
| Q1 2017 | 2017-03-31 | −1.01% | −4.23 pp |
| Q4 2016 | 2016-12-31 | −5.55% | +13.57 pp |
| Q3 2016 | 2016-09-30 | 2.30% | +1.84 pp |
| Q2 2016 | 2016-06-30 | 3.47% | +3.36 pp |
| Q1 2016 | 2016-03-31 | 3.22% | +5.66 pp |
| Q4 2015 | 2015-12-31 | −19.12% | −24.40 pp |
| Q3 2015 | 2015-09-30 | 0.45% | +0.77 pp |
| Q2 2015 | 2015-06-30 | 0.11% | −2.68 pp |
| Q1 2015 | 2015-03-31 | −2.44% | −4.60 pp |
| Q4 2014 | 2014-12-31 | 5.28% | −1.29 pp |
| Q3 2014 | 2014-09-30 | −0.31% | −7.18 pp |
| Q2 2014 | 2014-06-30 | 2.80% | −0.44 pp |
| Q1 2014 | 2014-03-31 | 2.17% | +0.22 pp |
| Q4 2013 | 2013-12-31 | 6.57% | +5.26 pp |
| Q3 2013 | 2013-09-30 | 6.87% | +11.69 pp |
| Q2 2013 | 2013-06-30 | 3.24% | −2.14 pp |
| Q1 2013 | 2013-03-31 | 1.95% | −3.73 pp |
| Q4 2012 | 2012-12-31 | 1.31% | −1.59 pp |
| Q3 2012 | 2012-09-30 | −4.82% | −5.19 pp |
| Q2 2012 | 2012-06-30 | 5.37% | +6.46 pp |
| Q1 2012 | 2012-03-31 | 5.68% | +13.75 pp |
| Q4 2011 | 2011-12-31 | 2.90% | — |
| Q3 2011 | 2011-09-30 | 0.37% | +11.99 pp |
| Q2 2011 | 2011-06-30 | −1.09% | +8.30 pp |
| Q1 2011 | 2011-03-31 | −8.07% | — |
| Q3 2010 | 2010-09-30 | −11.62% | — |
| Q2 2010 | 2010-06-30 | −9.39% | — |
Over the last five fiscal years, Neogenomics's operating margin decreased from −3.15% to −15.93%, a change of −12.78 percentage points. The latest reported quarter, Q2 2026, shows −4.85%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Neogenomics source filings ↗